Eflapegrastim BLA under FDA review; PDUFA date September 9, 2022
FDA completes re-inspection of drug substance manufacturing facility for eflapegrastim
Poziotinib NDA under FDA review with ODAC meeting on September 22, 2022
Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT
Conference Call
Thursday, August 11, 2022 @ 8:30 a.m. Eastern/5:30 a.m. Pacific
To access the live call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, participants are encouraged to dial into the conference call fifteen minutes ahead of the scheduled start time.
This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals' website: https://investor.sppirx.com/events-and-presentations on August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific.
https://finance.yahoo.com/news/spectrum-pharmaceuticals-reports-second-quarter-120000882.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.